You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
邁瑞醫療(300760.SZ):今年公司化學發光業務的國內市佔率有望再超一家進口品牌
格隆匯 07-30 08:46

格隆匯7月30日丨邁瑞醫療(300760.SZ)近日接受特定對象調研時表示,化學發光業務作為過去幾年和未來相當長一段時間拉動公司增長的重要業務,邁瑞始終高度重視該業務的發展情況,研發、營銷、供應鏈端持續對該業務進行高比例投入。

其中,公司一項重大投入便是收購海肽生物。在收購完成後的近三年時間裏,海肽生物的整合工作進展順利,去年便推出了行業領先的高敏肌鈣蛋白hs-cTnl。今年,國際臨牀化學和實驗室醫學聯盟(IFCC)在更新的全球主要IVD廠家肌鈣蛋白試劑性能參考表中,邁瑞在全部hs-cTnI試劑中排名第一。優異的試劑性能使得公司心肌標誌物項目的收入在去年的增速超過了60%,遠超化學發光業務的平均增速。

在試劑性能持續提升的過程中,公司IVD儀器的技術水平已經逐步達到了行業領先的水平,其中的重磅新品便是今年推出的MT8000全實驗室智能化流水線(二期)。

接下來TLA流水線的裝機也將放量,推動公司IVD業務進入更多的國內大醫院和海外中大樣本量客户。

據公司統計,今年公司化學發光業務的國內市佔率有望再超一家進口品牌。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account